Nikola Ptáková

Nikola Ptáková

Auto-generated profile, based on publicly available information

Nikola Ptáková

Biopticka Laborator, Ltd Plzen Czech Republic

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
NKNaoto Kuroda
Naoto Kuroda
Kiril TrpkovKiril Trpkov
Kiril Trpkov
YGYuan Gao
Yuan Gao
MTMaria Tretiakova
Maria Tretiakova
YLYajuan J. Liu
Yajuan J. Liu
Ondrej HesOndrej Hes
Ondrej Hes

1 March 2022 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
MFMihaela Farcaş
Mihaela Farcaş
ZGZoran Gatalica
Zoran Gatalica
Kiril TrpkovKiril Trpkov
Kiril Trpkov
JSJeffrey Swensen
Jeffrey Swensen
MZMing Zhou
Ming Zhou
Ondrej HesOndrej Hes
Ondrej Hes

4 October 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
MMMichael Michal
Michael Michal
BRBrian P. Rubin
Brian P. Rubin
Abbas AgaimyAbbas Agaimy
Abbas Agaimy
KKKemal Kosemehmetoglu
Kemal Kosemehmetoglu
ERErin R. Rudzinski
Erin R. Rudzinski
ZYZerife Yusufli
Zerife Yusufli

9 February 2024 in The Journal of Pathology
Verified
Journal Article
Open access
NKNatálie Klubíčková
Natálie Klubíčková
JDJosephine K Dermawan
Josephine K Dermawan
EMElaheh Mosaieby
Elaheh Mosaieby
PMPetr Martínek
Petr Martínek
TVTomáš Vaněček
Tomáš Vaněček
MMMichael Michal
Michael Michal
Alterations in kinase genes such as NTRK1/2/3 , RET , and BRAF underlie infantile fibrosarcoma (IFS), the emerging entity ‘ NTRK ‐rearranged spindle cell neoplasms’ included in the latest WHO classification, and a growing set of tumors with overlapping clinical and pathological features. In this study, we conducted a comprehensive clinicopathological and molecular analysis of 22 cases of IFS and other kinase gene‐altered spindle cell neoplasms affecting both pediatric and adult patients. Follow‐up periods for 16 patients ranged in length from 10 to 130 months (mean 38 months). Six patients were treated with targeted therapy, achieving a partial or complete response in five cases. Overall, three cases recurred and one metastasized. Eight patients were free of disease, five were alive with disease, and two patients died. All cases showed previously reported morphological patterns. Based on the cellularity and level of atypia, cases were divided into three morphological grade groups. S100 protein and CD34 were at least focally positive in 12/22 and 14/22 cases, respectively. Novel PWWP2A::RET , NUMA1::RET , ITSN1::RAF1 , and CAPZA2::MET fusions, which we report herein in mesenchymal tumors for the first time, were detected by RNA sequencing. Additionally, the first uterine case with BRAF and EGFR mutations and CD34 and S100 co‐expression is described. DNA sequencing performed in 13 cases uncovered very rare additional genetic aberrations. The CNV profiles showed that high‐grade tumors demonstrate a significantly higher percentage of copy number gains and losses across the genome compared with low‐ and intermediate‐grade tumors. Unsupervised clustering of the tumors’ methylation profiles revealed that in 8/9 cases, the methylation profiles clustered with the IFS methylation class, irrespective of their clinicopathological or molecular features. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

14 April 2020 in Laboratory Investigation
Verified
Journal Article
Closed access
PDF file
DSDavid Suster
David Suster
MMMichael Michal
Michael Michal
MNMichiya Nishino
Michiya Nishino
SPSimonetta Piana
Simonetta Piana
MBMassimo Bongiovanni
Massimo Bongiovanni
SSSaul Suster
Saul Suster

10 March 2022 in Bosnian Journal of Basic Medical Sciences
Verified
Journal Article
Open access
PDF file
JRJoanna Rogala
Joanna Rogala
FKFumiyoshi Kojima
Fumiyoshi Kojima
RAReza Alaghehbandan
Reza Alaghehbandan
NPNikola Ptakova
Nikola Ptakova
ABAna Bravc
Ana Bravc
Ondrej HesOndrej Hes
Ondrej Hes
Chromophobe renal cell carcinoma (CHRCC) is known for morphologic variability. Besides classic morphology, several other patterns like pigmented adenomatoid, multicystic, even papillary were documented. 10 cases of CHRCC composed of small cell population in various percentages that were analysed using morphologic parameters, immunohistochemistry and next generation sequencing. Patients were 5 males and 5 females with 40-78 age range. Size of tumors ranged from 2.2 cm to 11 cm (mean 5.17 cm). Small cell component comprised 10-80% of total tumor volume, the rest was formed by cells with classic morphology. Immunohistochemical profile followed typical CHRCC immunophenotype with positivity for CD117, CK7 among others. Neuroendocrine markers were negative. Mutations of 13 genes were found: DCIER1, FGFR3, JAK3, SUFO, FAM46C, FANCG, MET, PLCG2, APC, POLE, EPICAM, MUTYH, AR. However, only mutation of PLCG2 is listed as pathogenic. Recognition of small cell variant of CHRCC is not problematic in tumors, where “classic” CHRCC component is present. In limited material, like core biopsy, recognising this pattern could be troublesome. Very problematic might be in limited material like core biopsy. From our limited data it seems, that small cell morphology has no influence on prognosis.